{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:28:20Z","timestamp":1777418900425,"version":"3.51.4"},"reference-count":12,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2004,2,1]],"date-time":"2004-02-01T00:00:00Z","timestamp":1075593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2004,2]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>The development of hyperlipidemia after liver transplant is frequently treated with hydroxymethylglutaryl coenzyme A reductase inhibitors (statins) such as atorvastatin. As atorvastatin and the primary immunosuppressant drug, cyclosporine, are metabolized by the same pathway, there is the potential for an interaction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To determine the effect of atorvastatin on cyclosporine pharmacokinetics in liver transplant recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>Six stable, long-term adult liver transplant recipients from a single center who developed posttransplant dyslipidemia were recruited to participate in a 14-day, open-label study of atorvastatin 10 mg\/d coadministered with standard posttransplant immunosuppression using constant oral doses of cyclosporine and corticosteroids. A 10-point pharmacokinetic profile was performed prior to and on day 14 after commencement of atorvastatin therapy. Cyclosporine concentrations were measured by HPLC-electrospray-tandem mass spectrometry. The AUC was calculated by the linear trapezoidal rule, with other parameters determined by visual inspection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Atorvastatin coadministration increased the cyclosporine AUC by 9% (range 0\u201320.6%; 3018 vs 3290 ng\u2022h\/mL; p = 0.04). No significant change was evident for other cyclosporine pharmacokinetic parameters. Total cholesterol and low-density lipoprotein cholesterol levels were significantly lower on day 14 than at baseline (p &lt; 0.02). One patient developed a twofold increase in transaminases after 2 weeks of atorvastatin therapy, but no other clinical or biochemical adverse events were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Atorvastatin coadministration increases the cyclosporine AUC by approximately 10% in stable liver transplant recipients. This change in systemic exposure to cyclosporine is of questionable clinical significance. Atorvastatin is effective in reducing cholesterol levels in liver transplant recipients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1d388","type":"journal-article","created":{"date-parts":[[2004,1,12]],"date-time":"2004-01-12T12:02:56Z","timestamp":1073908976000},"page":"205-208","source":"Crossref","is-referenced-by-count":33,"title":["Effect of Atorvastatin on Cyclosporine Pharmacokinetics in Liver Transplant Recipients"],"prefix":"10.1177","volume":"38","author":[{"given":"Paul J","family":"Taylor","sequence":"first","affiliation":[{"name":"Paul J Taylor BSc, Senior Scientist, Department of Medicine, University of Queensland, Department of Clinical Pharmacology, Princess Alexandra Hospital, Brisbane, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A","family":"Kubler","sequence":"additional","affiliation":[{"name":"Paul A Kubler FRACP, Registrar, Department of Clinical Pharmacology, Princess Alexandra Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen V","family":"Lynch","sequence":"additional","affiliation":[{"name":"Stephen V Lynch FRACS, Associate Professor of Surgery, Department of Surgery, University of Queensland, Princess Alexandra Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Allen","sequence":"additional","affiliation":[{"name":"Joan Allen RN, Nurse Practice Coordinator\u2014Transplant Services, Princess Alexandra Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maree","family":"Butler","sequence":"additional","affiliation":[{"name":"Maree Butler RN, Clinical Nurse, Liver Transplant Recipient Coordinator, Queensland Liver Transplant Service, Princess Alexandra Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter I","family":"Pillans","sequence":"additional","affiliation":[{"name":"Peter I Pillans FRACP, Director, Department of Clinical Pharmacology, Princess Alexandra Hospital; Senior Lecturer, Department of Medicine, University of Queensland, Princess Alexandra Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2004,2,1]]},"reference":[{"key":"bibr1-aph.1D388","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)91766-3"},{"key":"bibr2-aph.1D388","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199410273311702"},{"key":"bibr3-aph.1D388","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V48s37"},{"key":"bibr4-aph.1D388","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199511163332001"},{"key":"bibr5-aph.1D388","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-6143.2001.10415.x"},{"key":"bibr6-aph.1D388","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/16.1.141"},{"key":"bibr7-aph.1D388","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/15.9.1446"},{"key":"bibr8-aph.1D388","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200363040-00003"},{"key":"bibr9-aph.1D388","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241110-00003"},{"key":"bibr10-aph.1D388","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241050-00003"},{"key":"bibr11-aph.1D388","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.1996.34412.x"},{"key":"bibr12-aph.1D388","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-1345(98)00393-5"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1D388","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1D388","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1D388","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:08:37Z","timestamp":1777374517000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1D388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,2]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2004,2]]}},"alternative-id":["10.1345\/aph.1D388"],"URL":"https:\/\/doi.org\/10.1345\/aph.1d388","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,2]]}}}